Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KH658 ophthalmic injection in diabetic macular edema
CTR20262619Phase 2Active
- Sponsor
- Chengdu Hongji Biotech
- Start
- Jul 2026
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of KH658 in diabetic macular edema (DME), sponsored by Chengdu Hongji Biotech. Started Jul 2026; status: active.
02
Drugs
KH658
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20262619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262619.